Influence of triptans use on anti-CGRP mAbs response: a prospective, cohort study.

IF 4.8 2区医学 Q1 CLINICAL NEUROLOGY

Journal of Neurology Pub Date : 2025-06-19 DOI:10.1007/s00415-025-13202-0

Catello Vollono, Marina Romozzi, Antonio Munafò, Giulia Vigani, Francesco De Cesaris, Paolo Calabresi, Luigi Francesco Iannone

{"title":"Influence of triptans use on anti-CGRP mAbs response: a prospective, cohort study.","authors":"Catello Vollono, Marina Romozzi, Antonio Munafò, Giulia Vigani, Francesco De Cesaris, Paolo Calabresi, Luigi Francesco Iannone","doi":"10.1007/s00415-025-13202-0","DOIUrl":null,"url":null,"abstract":"Background: This study aimed to compare the differences in clinical characteristics and response to monoclonal antibodies against CGRP (anti-CGRP mAbs) between patients who habitually used triptans (TRIPTANS group) and patients who were non-current users (NO-TRIPTANS group).Methods: In this prospective cohort study, all consecutive outpatients treated with anti-CGRP mAbs for 12 months were included. Clinical data were collected at baseline and monthly: number of headache days (MHDs), the absolute number of analgesics (AMNs), and the number of days with at least one analgesic (AMDs), Headache Impact Test-6 (HIT-6), and Migraine Disability Assessment (MIDAS) questionnaires. The outcomes were to evaluate the differences between TRIPTANS and NO-TRIPTANS groups (users or non-users of triptans in the 6 months before and during anti-CGRP mAb treatment) in MHDs and the other clinical variables during treatment. Response rates were assessed based on reductions in MHDs (≤ 25%, ≥ 50%, ≥ 75%).Results: A total of 336 patients treated with mAbs were included. At baseline, NO-TRIPTANS group had higher MHDs (24.7 ± 6.7) compared to the TRIPTANS group (21.8 ± 6.9), p < 0.001. Comparative and normalized analyses showed significant and sustained lower MHDs in the TRIPTANS group during treatment. The MIDAS score was also significantly lower in the TRIPTANS group at month-3, 6, 9, 12, and lower AMDs and AMNs compared to NO-TRIPTANS group were seen in most of the time-points. The number of patients with ≥ 50% reduction of MHDs was significantly higher in the TRIPTANS group at months 1 and 12.Conclusions: This study showed greater effectiveness of anti-CGRP mAb in habitual triptans users, possibly due to a common and/or synergistic action.","PeriodicalId":16558,"journal":{"name":"Journal of Neurology","volume":"272 7","pages":"468"},"PeriodicalIF":4.8000,"publicationDate":"2025-06-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Neurology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s00415-025-13202-0","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"CLINICAL NEUROLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Background: This study aimed to compare the differences in clinical characteristics and response to monoclonal antibodies against CGRP (anti-CGRP mAbs) between patients who habitually used triptans (TRIPTANS group) and patients who were non-current users (NO-TRIPTANS group).

Methods: In this prospective cohort study, all consecutive outpatients treated with anti-CGRP mAbs for 12 months were included. Clinical data were collected at baseline and monthly: number of headache days (MHDs), the absolute number of analgesics (AMNs), and the number of days with at least one analgesic (AMDs), Headache Impact Test-6 (HIT-6), and Migraine Disability Assessment (MIDAS) questionnaires. The outcomes were to evaluate the differences between TRIPTANS and NO-TRIPTANS groups (users or non-users of triptans in the 6 months before and during anti-CGRP mAb treatment) in MHDs and the other clinical variables during treatment. Response rates were assessed based on reductions in MHDs (≤ 25%, ≥ 50%, ≥ 75%).

Results: A total of 336 patients treated with mAbs were included. At baseline, NO-TRIPTANS group had higher MHDs (24.7 ± 6.7) compared to the TRIPTANS group (21.8 ± 6.9), p < 0.001. Comparative and normalized analyses showed significant and sustained lower MHDs in the TRIPTANS group during treatment. The MIDAS score was also significantly lower in the TRIPTANS group at month-3, 6, 9, 12, and lower AMDs and AMNs compared to NO-TRIPTANS group were seen in most of the time-points. The number of patients with ≥ 50% reduction of MHDs was significantly higher in the TRIPTANS group at months 1 and 12.

Conclusions: This study showed greater effectiveness of anti-CGRP mAb in habitual triptans users, possibly due to a common and/or synergistic action.

查看原文本刊更多论文

曲坦类药物使用对抗cgrp单克隆抗体反应的影响：一项前瞻性队列研究

背景：本研究旨在比较习惯性使用曲坦类药物的患者（曲坦组）和非当前使用曲坦类药物的患者（无曲坦类药物组）的临床特征和抗CGRP单克隆抗体（抗CGRP单克隆抗体）的差异。方法：在这项前瞻性队列研究中，纳入所有连续接受抗cgrp单克隆抗体治疗12个月的门诊患者。在基线和每月收集临床数据：头痛天数（mhd）、镇痛药的绝对数量（AMNs）和至少使用一种镇痛药的天数（AMDs）、头痛影响测试-6 （HIT-6）和偏头痛残疾评估（MIDAS）问卷。结果是评估曲坦类药物组和非曲坦类药物组（抗cgrp单抗治疗前6个月和治疗期间使用或不使用曲坦类药物组）在mhd和治疗期间其他临床变量的差异。根据mhd的减少（≤25%,≥50%,≥75%）评估缓解率。结果：共纳入336例接受单抗治疗的患者。在基线时，无曲坦类药物组的mhd（24.7±6.7）高于曲坦类药物组（21.8±6.9），p结论：本研究显示抗cgrp单抗在习惯性曲坦类药物使用者中更有效，可能是由于共同和/或协同作用。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Journal of Neurology 医学-临床神经学

CiteScore

10.00

自引率

5.00%

发文量

558

审稿时长

1 months

期刊介绍： The Journal of Neurology is an international peer-reviewed journal which provides a source for publishing original communications and reviews on clinical neurology covering the whole field. In addition, Letters to the Editors serve as a forum for clinical cases and the exchange of ideas which highlight important new findings. A section on Neurological progress serves to summarise the major findings in certain fields of neurology. Commentaries on new developments in clinical neuroscience, which may be commissioned or submitted, are published as editorials. Every neurologist interested in the current diagnosis and treatment of neurological disorders needs access to the information contained in this valuable journal.